Participated · Seed · Jun 2026

ConeLabs develops a digital infrastructure inspection platform that converts field imagery into detailed 3D models, automatically detects structural defects, and generates structured engineering reports. Its system is used by engineering firms and public agencies to speed inspections, reduce manual workload, and standardize asset condition data for maintenance decisions. The company participated in the Techstars accelerator program in 2023 and is led by founder and CEO Albert Mansour. ConeLabs aims to replace manual, paper-based inspection workflows with faster, data-driven processes. Following the $1.5M pre-seed raise, the company plans to use the capital to expand sales and scale its presence in infrastructure markets.

Participated · Seed · May 2026

Synakis is developing ocular products built on a proprietary hydrogel platform designed for vitreous replacement and sustained therapeutic delivery. Its lead candidate, SNK-125, is a vitreous replacement therapy intended to address complications associated with current gas and oil treatments for retinal detachment. The company is pre-clinical and was spun out of Professor Molly Shoichet’s laboratory at the University of Toronto. Synakis recently raised CAD $2.6 million in an oversubscribed pre-seed round to advance GLP toxicology studies and carry out lead optimization. The firm plans to complete GLP toxicology by early 2027 to support an ITA filing with Health Canada. The announcement notes independent validation of the hydrogel platform and quotes company leadership and investor representatives on the scientific rigor and unmet clinical need.

Participated · Seed · Aug 2025

Crewscope is a jobsite productivity platform that combines weekly planning, real-time progress feedback, and performance-based incentives specifically for field crews. The platform is built for critical-path trades and was developed and proven in the field with developers, general contractors, mining operations, and civil contractors. Customers report measurable impacts including up to 10% gains in labor productivity, improved forecast accuracy, and stronger team retention, and workers report increased motivation and focus. Founded in 2023 and commercially launched in 2024, the Toronto startup is already trusted by leading developers and contractors such as Hazelview Investments, Lanterra Developments, EllisDon, Amrize/LafargeHolcim, and Maple Reinders. Crewscope plans to use new funding to expand across North America, scale predictive AI capabilities, reduce schedule risk, and help clients build higher-performance field teams. The product targets persistent industry challenges including long-term productivity declines and impending workforce retirements by aligning site teams around the critical path and recognizing performance.

Participated · Seed · Sep 2024

HDAX Therapeutics is developing best-in-class HDAC6-targeting small-molecule therapeutics via a novel molecular recognition mechanism aimed at overcoming weak binding, poor pharmacokinetics, and off-target toxicities. The company’s platform originates from over seven years of research in Professor Patrick Gunning’s lab at the University of Toronto. HDAX is focused on discovery and preclinical development toward candidate nomination across neurological and cardiometabolic indications. Management emphasizes the potential for differentiated safety and efficacy versus prior HDAC6 efforts. The company is privately held and plans to use proceeds from its seed financing to advance its pipeline programs and nominate a preclinical development candidate. HDAX highlights a leadership team with deep small-molecule development expertise.

Participated · Series D · Jul 2024

TMRW Life Sciences produces an FDA-cleared automated platform for the safe management and storage of frozen sperm, eggs, and embryos, using digital identification, robotics, and remote monitoring. Its systems reduce potential points of failure by 94% compared to manual processes. The company partners with fertility clinics to digitize the IVF lab and enable around-the-clock specimen oversight. TMRW now works with more than 60 fertility clinic partners, serves over 39,000 patients, and manages more than 260,000 frozen specimens. Led by CEO Louis Villalba, the company plans to use new funding to expand operations and boost R&D. TMRW Life Sciences offers an automated platform for storing, tracking, and monitoring frozen eggs and embryos used in in vitro fertilization, combining robotics, RFID technology, 24/7 remote monitoring, and integrated software. Led by CEO Tara Comonte, the company launched commercially and in its first six months has been adopted by prominent U.S. fertility clinics including Vios Fertility Institute, Conceptions Reproductive Associates of Colorado, San Diego Fertility Center, Boston IVF, and CCRM. On July 20, 2021, TMRW completed a $105M Series C financing that included both equity and debt. The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others; Signature Bank increased its existing debt facility. The company intends to use the proceeds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities. The platform's core capabilities focus on traceability and safe maintenance of reproductive tissue at cryogenic temperatures to reduce human error and improve lab workflows. TMRW Life Sciences offers a combined physical and digital chain-of-custody solution that tracks and protects eggs, embryos, and sperm using RFID-enabled hardware and a SaaS digital platform. Its software-guided embryology and cryo-management system is designed to eliminate sample-management errors reported in the fertility space, including loss of samples and implantation mix-ups. The company reports five leading clinic partners that together account for 10% of U.S. IVF activity and are preparing for a commercial rollout in Q1 2020. TMRW is led by co-CEOs Alan Murray and Joshua Abram; the third co-founder is Dr. Jeffrey Port. With the Series B closing, TMRW appointed Melanie Goldey as Chief Operating Officer and Chief Financial Officer; Goldey was previously CFO of Refinery29. The product and commercial plans are positioned to scale through clinic partnerships and the planned rollout.